Andre C Kalil

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5501427/publications.pdf

Version: 2024-02-01

207	18,859	31976 53	12946 131
papers	citations	h-index	g-index

207	207	207	28358
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Remdesivir for the Treatment of Covid-19 â€" Final Report. New England Journal of Medicine, 2020, 383, 1813-1826.	27.0	5,834
2	Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases, 2016, 63, e61-e111.	5.8	2,405
3	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine, 2021, 384, 795-807.	27.0	1,398
4	Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis. JAMA - Journal of the American Medical Association, 2013, 309, 1154.	7.4	625
5	Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Critical Care Medicine, 2008, 36, 1330-1349.	0.9	549
6	Treating COVID-19â€"Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA - Journal of the American Medical Association, 2020, 323, 1897.	7.4	396
7	Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*. Critical Care Medicine, 2003, 31, 834-840.	0.9	359
8	Risk and the Efficacy of Antiinflammatory Agents. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1197-1205.	5.6	344
9	Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. Annals of Internal Medicine, 2005, 143, 870.	3.9	344
10	Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases, 2016, 63, 575-582.	5.8	334
11	Influenza virus-related critical illness: pathophysiology and epidemiology. Critical Care, 2019, 23, 258.	5.8	286
12	An Immune Reconstitution Syndrome-Like Illness Associated withCryptococcus neoformans Infection in Organ Transplant Recipients. Clinical Infectious Diseases, 2005, 40, 1756-1761.	5.8	243
13	Long-term consequences of COVID-19: research needs. Lancet Infectious Diseases, The, 2020, 20, 1115-1117.	9.1	241
14	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVIDâ€19 Pandemic: Version 3. Arthritis and Rheumatology, 2021, 73, e1-e12.	5.6	201
15	Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit*. Critical Care Medicine, 2009, 37, 2350-2358.	0.9	198
16	Pulmonary Cryptococcosis in Solid Organ Transplant Recipients: Clinical Relevance of Serum Cryptococcal Antigen. Clinical Infectious Diseases, 2008, 46, e12-e18.	5.8	163
17	Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients WithStaphylococcus aureusBloodstream Infections. JAMA - Journal of the American Medical Association, 2014, 312, 1552.	7.4	152
18	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVIDâ€19 Pandemic: Version 1. Arthritis and Rheumatology, 2020, 72, 1241-1251.	5.6	142

#	Article	IF	Citations
19	Safety, Pharmacokinetics, and Pharmacodynamics of Drotrecogin Alfa (Activated) in Children With Severe Sepsis. Pediatrics, 2004, 113, 7-17.	2.1	133
20	Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clinical Infectious Diseases, 2018, 66, 1631-1635.	5.8	132
21	Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis*. Critical Care Medicine, 2010, 38, 1802-1808.	0.9	122
22	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1365-1376.	10.7	119
23	Ebola virus disease: an update on post-exposure prophylaxis. Lancet Infectious Diseases, The, 2018, 18, e183-e192.	9.1	112
24	O-GlcNAc Transferase Suppresses Inflammation and Necroptosis by Targeting Receptor-Interacting Serine/Threonine-Protein Kinase 3. Immunity, 2019, 50, 576-590.e6.	14.3	111
25	Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2014, 58, 5262-5268.	3.2	109
26	Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. Clinical Infectious Diseases, 2021, 72, 541-552.	5.8	103
27	Is Bacteremic Sepsis Associated With Higher Mortality in Transplant Recipients Than in Nontransplant Patients? A Matched Case-Control Propensity-Adjusted Study. Clinical Infectious Diseases, 2015, 60, 216-222.	5.8	98
28	Early Goal-Directed Therapy for Sepsis: A Novel Solution for Discordant Survival Outcomes in Clinical Trials. Critical Care Medicine, 2017, 45, 607-614.	0.9	97
29	Use of Interferon-Â in Patients with West Nile Encephalitis: Report of 2 Cases. Clinical Infectious Diseases, 2005, 40, 764-766.	5.8	95
30	Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open, 2019, 5, e000935.	3.8	92
31	Calcineurin Inhibitor Agents Interact Synergistically with Antifungal Agents In Vitro against Cryptococcus neoformans Isolates: Correlation with Outcome in Solid Organ Transplant Recipients with Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 735-738.	3.2	91
32	Risk of COVIDâ€19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in Atâ€Risk Individuals. Arthritis and Rheumatology, 2021, 73, 2179-2188.	5.6	89
33	Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. The Cochrane Library, 2014, , CD006482.	2.8	88
34	Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review. Clinical Microbiology and Infection, 2021, 27, 47-54.	6.0	88
35	West Nile Virus--Associated Encephalitis in Recipients of Renal and Pancreas Transplants: Case Series and Literature Review. Clinical Infectious Diseases, 2004, 38, 1257-1260.	5.8	85
36	Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia. Shock, 2004, 21, 222-229.	2.1	84

#	Article	IF	Citations
37	New filovirus disease classification and nomenclature. Nature Reviews Microbiology, 2019, 17, 261-263.	28.6	84
38	Unrecognized Pretransplant and Donorâ€Derived Cryptococcal Disease in Organ Transplant Recipients. Clinical Infectious Diseases, 2010, 51, 1062-1069.	5.8	80
39	Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease. Clinical Infectious Diseases, 2015, 61, 969-973.	5.8	75
40	Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy. PLoS ONE, 2009, 4, e5512.	2.5	74
41	Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infectious Diseases, The, 2012, 12, 678-686.	9.1	73
42	A Direct and Indirect Comparison Meta-Analysis on the Efficacy of Cytomegalovirus Preventive Strategies in Solid Organ Transplant. Clinical Infectious Diseases, 2014, 58, 785-803.	5.8	73
43	Antifungal Management Practices and Evolution of Infection in Organ Transplant Recipients with Cryptococcus Neoformans Infection. Transplantation, 2005, 80, 1033-1039.	1.0	70
44	Preclinical trial of l-arginine monotherapy alone or with N-acetylcysteine in septic shock*. Critical Care Medicine, 2006, 34, 2719-2728.	0.9	70
45	Pneumonia with bacterial and viral coinfection. Current Opinion in Critical Care, 2017, 23, 385-390.	3.2	66
46	Is there a role for oral human immunoglobulin in the treatment for norovirus enteritis in immunocompromised patients?. Pediatric Transplantation, 2011, 15, 718-721.	1.0	65
47	Sepsis and Solid Organ Transplantation. Current Drug Targets, 2007, 8, 533-541.	2.1	64
48	Adenovirus Infections in Pediatric Small Bowel Transplant Recipients. Transplantation, 2010, 90, 198-204.	1.0	64
49	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVIDâ€19 Pandemic: Version 2. Arthritis and Rheumatology, 2020, 72, e1-e12.	5.6	64
50	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 888-899.	10.7	62
51	Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open, 2013, 3, e003912.	1.9	61
52	Lipid Formulations of Amphotericin B Significantly Improve Outcome in Solid Organ Transplant Recipients with Central Nervous System Cryptococcosis. Clinical Infectious Diseases, 2009, 49, 1721-1728.	5.8	57
53	Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysis. Clinical Infectious Diseases, 2011, 52, 313-321.	5.8	57
54	Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Medicine, 2011, 37, 420-429.	8.2	55

#	Article	IF	Citations
55	The complex link between influenza and severe sepsis. Virulence, 2014, 5, 137-142.	4.4	49
56	Lessons Learned. Critical Care Medicine, 2015, 43, 1157-1164.	0.9	49
57	Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients. Intensive Care Medicine, 2019, 45, 573-591.	8.2	48
58	Recommendations for the Assessment and Reporting of Multivariable Logistic Regression in Transplantation Literature. American Journal of Transplantation, 2010, 10, 1695-1703.	4.7	46
59	Bloodstream Infections During the First Year After Pediatric Small Bowel Transplantation. Pediatric Infectious Disease Journal, 2012, 31, 700-704.	2.0	45
60	L-Arginine supplementation in sepsis: beneficial or harmful?. Current Opinion in Critical Care, 2006, 12, 303-308.	3.2	43
61	Unresolved Questions With the Use of Linezolid vs Vancomycin for Nosocomial Pneumonia. Chest, 2004, 125, 2370-2371.	0.8	38
62	Why Are Clinicians Not Embracing the Results from Pivotal Clinical Trials in Severe Sepsis? A Bayesian Analysis. PLoS ONE, 2008, 3, e2291.	2.5	35
63	The use and value of procalcitonin in solid organ transplantation. Clinical Transplantation, 2015, 29, 689-696.	1.6	35
64	Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis. Shock, 2011, 36, 327-331.	2.1	33
65	Bayesian Methodology for the Design and Interpretation of Clinical Trials in Critical Care Medicine. Critical Care Medicine, 2014, 42, 2267-2277.	0.9	33
66	Sepsis in the Severely Immunocompromised Patient. Current Infectious Disease Reports, 2015, 17, 487.	3.0	33
67	Evaluation of an Infrared Thermal Detection System for Fever Recognition during the H1N1 Influenza Pandemic. Infection Control and Hospital Epidemiology, 2011, 32, 504-506.	1.8	30
68	Critical Care for Multiple Organ Failure Secondary to Ebola Virus Disease in the United States*. Critical Care Medicine, 2015, 43, 2066-2075.	0.9	30
69	Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit. Infectious Disorders - Drug Targets, 2011, 11, 354-364.	0.8	29
70	Identifying Predictors of Central Nervous System Disease in Solid Organ Transplant RecipientsWith Cryptococcosis. Transplantation, 2010, 89, 69-74.	1.0	28
71	Risk of cytomegalovirus disease in highâ€risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and metaâ€analysis. Liver Transplantation, 2012, 18, 1440-1447.	2.4	28
72	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 1349-1351.	10.7	28

#	Article	IF	Citations
73	An International Survey of Cytomegalovirus Prevention and Treatment Practices in Intestinal Transplantation. Transplantation, 2014, 97, 78-82.	1.0	27
74	Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infectious Diseases, 2017, 17, 385.	2.9	26
75	Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?. Clinical Transplantation, 2008, 22, 222-228.	1.6	24
76	Is cytomegalovirus reactivation increasing the mortality of patients with severe sepsis?. Critical Care, 2011, 15, 138.	5.8	24
77	Management of Ventilator-Associated Pneumonia. Clinics in Chest Medicine, 2018, 39, 797-808.	2.1	24
78	Severe infections in critically ill solid organ transplant recipients. Clinical Microbiology and Infection, 2018, 24, 1257-1263.	6.0	23
79	Is cefepime safe for clinical use? A Bayesian viewpoint. Journal of Antimicrobial Chemotherapy, 2011, 66, 1207-1209.	3.0	22
80	Predictors of persistent diarrhea in norovirus enteritis after solid organ transplantation. Clinical Transplantation, 2016, 30, 1488-1493.	1.6	22
81	Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. , 2008, , CD006482.		20
82	Risk Factors for Systemic Candida Infections in Pediatric Small Bowel Transplant Recipients. Pediatric Infectious Disease Journal, 2012, 31, 120-123.	2.0	20
83	Does increasing immunoglobulin levels impact survival in solid organ transplant recipients with hypogammaglobulinemia?. Clinical Transplantation, 2014, 28, 1249-1255.	1.6	20
84	Incidence of ventilator associated pneumonia in burn patients with inhalation injury treated with high frequency percussive ventilation versus volume control ventilation: A systematic review. Burns, 2016, 42, 1193-1200.	1.9	20
85	A silent killer: Cytomegalovirus infection in the nonimmunocompromised critically ill patient*. Critical Care Medicine, 2008, 36, 3261-3264.	0.9	19
86	Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?. Current Infectious Disease Reports, 2015, 17, 494.	3.0	18
87	Sepsis in Immunocompromised Patients Without Human Immunodeficiency Virus. Journal of Infectious Diseases, 2020, 222, S156-S165.	4.0	18
88	Neutrophil inhibition with L-selectin-directed MAb improves or worsens survival dependent on the route but not severity of infection in a rat sepsis model. Journal of Applied Physiology, 2005, 98, 2155-2162.	2.5	17
89	Cerebral aspergillosis caused by Aspergillus ustus following orthotopic heart transplantation: case report and review of the literature. Clinical Transplantation, 2009, 23, 116-120.	1.6	16
90	Evaluation of the coagulation and inflammatory responses in solid organ transplant recipients and donors. Clinical Transplantation, 2009, 23, 943-950.	1.6	16

#	Article	IF	Citations
91	IMPACT Trial Results Should Not Change Current Standard of Care of 100 Days for Cytomegalovirus Prophylaxis. American Journal of Transplantation, 2011, 11, 18-21.	4.7	16
92	New guidelines for nosocomial pneumonia. Current Opinion in Pulmonary Medicine, 2017, 23, 211-217.	2.6	16
93	Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis. Critical Care, 2013, 17, 167.	5.8	15
94	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open, 2021, 3, 965-975.	1.5	15
95	Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19. Current Opinion in Critical Care, 2021, 27, 493-496.	3.2	15
96	Probiotics and antibiotic-associated diarrhoea. Lancet, The, 2014, 383, 29-30.	13.7	14
97	Sepsis and Challenging Infections in the Immunosuppressed Patient in the Intensive Care Unit. Infectious Disease Clinics of North America, 2017, 31, 415-434.	5.1	14
98	Lack of Benefit of High-Dose Vitamin C, Thiamine, and Hydrocortisone Combination for Patients With Sepsis. JAMA - Journal of the American Medical Association, 2020, 323, 419.	7.4	14
99	Staphylococcus aureusinfections in kidney transplantation: A matched case controlled study. Scandinavian Journal of Infectious Diseases, 2012, 44, 427-432.	1.5	13
100	A Randomized 2Ã—2 Factorial Trial, Part 1. Transplantation, 2015, 99, 197-209.	1.0	13
101	Chicken Soup in the Time of COVID. Chest, 2020, 158, 864-865.	0.8	12
102	Antibiotic Combination Therapy for Patients With Gram-Negative Septic Shock. Critical Care Medicine, 2017, 45, 1933-1936.	0.9	11
103	Is Early Goal-Directed Therapy Harmful to Patients With Sepsis and High Disease Severity?. Critical Care Medicine, 2017, 45, 1265-1267.	0.9	11
104	Should We Manage All Septic Patients Based on a Single Definition? An Alternative Approach. Critical Care Medicine, 2018, 46, 177-180.	0.9	11
105	Quick Sequential Organ Failure Assessment Is Not Good for Ruling Sepsis In or Out. Chest, 2019, 156, 197-199.	0.8	11
106	Carbapenem Antibiotics for the Empiric Treatment of Nosocomial Pneumonia. Chest, 2021, 159, 1041-1054.	0.8	11
107	Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort. , 2021, 3, e0474.		11
108	Anti-inflammatory Effects of Rosuvastatin in Healthy Subjects: A Prospective Longitudinal Study. Current Pharmaceutical Design, 2014, 20, 1156-1160.	1.9	11

#	Article	IF	Citations
109	Advanced Preparation Makes Research in Emergencies and Isolation Care Possible: The Case of Novel Coronavirus Disease (COVID-19). American Journal of Tropical Medicine and Hygiene, 2020, 102, 926-931.	1.4	11
110	Pediococcus acidilactici Endocarditis Successfully Treated with Daptomycin. Journal of Clinical Microbiology, 2012, 50, 1106-1108.	3.9	10
111	Emerging and Resistant Infections. Annals of the American Thoracic Society, 2014, 11, S193-S200.	3.2	10
112	Rethinking Ventilator Bundles*. Critical Care Medicine, 2018, 46, 1201-1203.	0.9	10
113	Changes in lung microbiome do not explain the development of ventilator-associated pneumonia. Intensive Care Medicine, 2019, 45, 1133-1135.	8.2	10
114	Strength of Recommendation and Quality of Evidence for Recommendations in Current Infectious Diseases Society of America Guidelines. Open Forum Infectious Diseases, 2021, 8, ofab033.	0.9	10
115	How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. Intensive Care Medicine, 2008, 34, 1804-1811.	8.2	9
116	Respiratory syncytial virus lower respiratory tract infection in a pediatric liver transplant recipient treated with oral ribavirin. Pediatric Transplantation, 2012, 16, E348-51.	1.0	9
117	Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
118	The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis. Critical Care Medicine, 2010, 38, S663-S667.	0.9	8
119	Cytomegalovirus reactivation and colitis after left ventricular assist device placement. International Journal of Infectious Diseases, 2013, 17, e348-e351.	3.3	8
120	Deciphering the Sepsis Riddle. Critical Care Medicine, 2013, 41, 2458-2460.	0.9	8
121	Viral and bacterial co-infection in pneumonia: do we know enough to improve clinical care?. Critical Care, 2017, 21, 19.	5.8	7
122	The last breath for inhaled antibiotics and VAP? Not so fast. Lancet Infectious Diseases, The, 2020, 20, 265-266.	9.1	7
123	Geographic differences in disease expression of cryptococcosis in solid organ transplant recipients in the United States. Annals of Transplantation, 2010, 15, 77-83.	0.9	7
124	Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis. Expert Review of Anti-Infective Therapy, 2014, 12, 881-896.	4.4	6
125	A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology. PLoS ONE, 2015, 10, e0139247.	2.5	6
126	To Procalcitonin, or Not to Procalcitonin?. Chest, 2019, 155, 1085-1087.	0.8	6

#	Article	IF	Citations
127	Do not just sit there, do something â€¦ but do no harm: the worrying aspects of COVID-19 experimental interventions. Intensive Care Medicine, 2021, 47, 896-898.	8.2	6
128	Does recombinant activated protein C work in patients with severe sepsis?*. Critical Care Medicine, 2010, 38, 1217-1220.	0.9	5
129	Risk Factors and Outcomes of Staphylococcus aureus Infections After Small Bowel and Multivisceral Transplantation. Pediatric Infectious Disease Journal, 2012, 31, 25-29.	2.0	5
130	Vitamin C Is Not Ready forÂPrime Time in Sepsis butÂaÂSolution Is Close. Chest, 2017, 152, 676.	0.8	5
131	Ceftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia. Lancet Infectious Diseases, The, 2018, 18, 229-231.	9.1	5
132	Toward a More Nuanced Approach to the Early Administration of Intravenous Fluids in Patients With Sepsis. JAMA Network Open, 2018, 1, e185844.	5.9	5
133	What Is the Best Treatment for Vancomycin-Resistant Enterococcal Bloodstream Infections?*. Critical Care Medicine, 2018, 46, 1700-1703.	0.9	5
134	Procalcitonin Predicts the Severity of Cystic Fibrosis Pulmonary Exacerbations and Readmissions in Adult Patients: A Prospective Cohort Study. Journal of Investigative Medicine, 2020, 68, 856-863.	1.6	5
135	Any Role for Biomarker-Guide Algorithms in Antibiotic Stewardship Programs?*. Critical Care Medicine, 2020, 48, 775-777.	0.9	5
136	Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?. Critical Care Medicine, 2021, Publish Ahead of Print, .	0.9	5
137	Molnupiravir: Is It Time to Move In or Move Out?. , 2022, 1, .		5
138	Meta-analysis under the spotlight: We must differentiate its limitations versus its prejudices. Critical Care Medicine, 2008, 36, 3124-3126.	0.9	4
139	Wanted: early goal-directed therapy for septic shockâ€”dead or alive, but not critically ill!. Intensive Care Medicine, 2010, 36, 1-3.	8.2	4
140	Should Multivisceral Transplantation Be Considered in Patients Colonized with Multidrug-ResistantPseudomonas aeruginosa?. Microbial Drug Resistance, 2012, 18, 74-78.	2.0	4
141	The â€œLast Breathâ€•of the Ventilator-Associated Pneumonia Surveillance Definition*. Critical Care Medicine, 2014, 42, 722-723.	0.9	4
142	Respiratory pathogen panels in the hospital: good or unnecessary?. Current Opinion in Infectious Diseases, 2017, 30, 226-230.	3.1	4
143	Mortality in Solid Organ Transplant Recipients Hospitalized for Covidâ€19. American Journal of Transplantation, 2021, 22, 12.	4.7	4
144	The Potential for Increasing Risk of Consent Refusal in COVID-19 Trials: Considering Underlying Reasons and Responses. Annals of the American Thoracic Society, 2022, 19, 1446-1447.	3.2	4

#	Article	IF	Citations
145	The Use of Dexamethasone in Bacterial Meningitis. Clinical Infectious Diseases, 2005, 40, 1061-1062.	5.8	3
146	Candida albicans Skin Abscess in a Heart Transplant Recipient. Infectious Diseases in Clinical Practice, 2010, 18, 243-246.	0.3	3
147	Is it time to replace l-arginine in severe sepsis?*. Critical Care Medicine, 2011, 39, 417-418.	0.9	3
148	Why Valganciclovir Should Not Be Indicated for Liver Recipients and High-Dose Acyclovir Should Not Be Removed From International Cytomegalovirus Guidelines. Transplantation, 2011, 91, e8-e9.	1.0	3
149	Cytomegalovirus and mortality in critical care patients. Critical Care Medicine, 2012, 40, 303-305.	0.9	3
150	Is the evidence for benefits from ventilator-associated pneumonia bundles reliable enough for implementation in a general hospital?*. Critical Care Medicine, 2012, 40, 348-350.	0.9	3
151	Blood Purification. Critical Care Medicine, 2013, 41, 2244-2245.	0.9	3
152	Should Heparin Be Used to Treat Patients With Severe Sepsis?*. Critical Care Medicine, 2015, 43, 694-695.	0.9	3
153	Clinical presentation and outcomes of norovirus infection in intestinal allograft compared to native intestine. Transplant Infectious Disease, 2017, 19, e12692.	1.7	3
154	Strategies for implementation of a multidisciplinary approach to the treatment of nosocomial infections in critically ill patients. Expert Review of Anti-Infective Therapy, 2021, 19, 759-767.	4.4	3
155	Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment*. Critical Care Medicine, 2021, 49, 1182-1186.	0.9	3
156	Survival Outcome of Sepsis in Recipients of Solid Organ Transplant. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 717-725.	2.1	3
157	Repurposed drugs for COVID-19: threshold and proof requirements for trials. Clinical Microbiology and Infection, 2021, 27, 1716-1717.	6.0	3
158	Diagnosis of pneumonia in the critically ill patient: Is it time to abandon bronchoscopy?*. Critical Care Medicine, 2008, 36, 344-345.	0.9	2
159	Can Serum Mannoseâ€Binding Lectin Levels Aid with the Diagnosis of Invasive Aspergillosis?. Clinical Infectious Diseases, 2009, 49, 1492-1495.	5.8	2
160	Misguided guidelines on noninvasive thermometry. Critical Care Medicine, 2009, 37, 383-384.	0.9	2
161	Positive Deviance and Hand Hygiene: More Questions than Answers. Infection Control and Hospital Epidemiology, 2010, 31, 978-979.	1.8	2
162	Linezolid does not show advantages over vancomycin in modulating the pulmonary immune response: How should we conciliate these new findings with the Zephyr trial results?*. Critical Care Medicine, 2011, 39, 2009-2010.	0.9	2

#	Article	IF	Citations
163	Therapeutic Hypothermia Is Cool, but Be Aware of the Infection Heat*. Critical Care Medicine, 2014, 42, 445-446.	0.9	2
164	Colouring outside the guidelines. Clinical Microbiology and Infection, 2017, 23, 691-692.	6.0	2
165	Emergence of Extended-Spectrum Beta-Lactamaseâ€“Producing Enterobacteriaceae Colonization. Critical Care Medicine, 2017, 45, 752-754.	0.9	2
166	Is Procalcitonin-Guided Therapy Associated With Beneficial Outcomes in Critically Ill Patients With Sepsis?*. Critical Care Medicine, 2018, 46, 811-812.	0.9	2
167	Reply to Al-Hasan and Justo. Clinical Infectious Diseases, 2019, 68, 1432-1432.	5.8	2
168	Can ceftolozaneâ€“tazobactam treat nosocomial pneumonia?. Lancet Infectious Diseases, The, 2019, 19, 1266-1267.	9.1	2
169	Less is more: critically ill status is not a carte blanche for unlimited antibiotic use. Intensive Care Medicine, 2020, 46, 2075-2078.	8.2	2
170	Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience. Transplantation Proceedings, 2021, 53, 1058-1063.	0.6	2
171	Sepsis and Septic Shock. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 639-640.	2.1	2
172	Are there more differences or similarities between the hospital-acquired pneumonia guidelines?. Annals of Translational Medicine, 2018, 6, 429-429.	1.7	2
173	Infections in Small Bowel Transplant Recipients. , 0, , 297-304.		1
174	Can we predict cytomegalovirus reactivation in critically ill patients?*. Critical Care Medicine, 2012, 40, 3313-3314.	0.9	1
175	Erratum for Gross et al., Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2014, 58, 6342-6342.	3.2	1
176	The authors reply. Critical Care Medicine, 2016, 44, e447-e448.	0.9	1
177	Secondary Infection in Patients With Sepsis. JAMA - Journal of the American Medical Association, 2016, 316, 771.	7.4	1
178	How to translate the new hospital-acquired and ventilator-associated pneumonia guideline to the bedside. Current Opinion in Critical Care, 2017, 23, 355-363.	3.2	1
179	Didnâ€™t inhale? Time to reconsider aerosolized antibiotics in the treatment of ventilator-associated pneumonia. Critical Care, 2018, 22, 333.	5.8	1
180	Saved From Sepsis. Critical Care Medicine, 2019, 47, 733-735.	0.9	1

#	Article	IF	Citations
181	A Sepsis Screening Tool for Hematopoietic Cell Transplant Recipients Remains Elusive. Clinical Infectious Diseases, 2021, 72, 1230-1231.	5.8	1
182	Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. Annals of Internal Medicine, 2006, 144, 457.	3.9	0
183	Reply to Sprung et al: steroid treatment for patients with severe sepsis and septic shock. Intensive Care Medicine, 2011, 37, 1567-1568.	8.2	0
184	Drotrecogin alfa (activated) in severe sepsis â€“ Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 110-111.	9.1	0
185	Hospital-Acquired Pneumonia. Critical Care Medicine, 2013, 41, 2232-2233.	0.9	0
186	Bayes' 250-year-old legacy for infectious diseases. Lancet Infectious Diseases, The, 2014, 14, 674-675.	9.1	0
187	Reply to Thomason et al and Bahr et al. Clinical Infectious Diseases, 2015, 60, 1870-1871.	5.8	0
188	Risk Factors Associated with Adenovirus Infection in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
189	Risk Factors for Clostridium difficile Infection (CDI) in Intestinal Transplant Recipients (ITR) during the First Year Post-Transplant.. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
190	Letter to the editor: â€˜challenges and opportunities in the treatment of ventilator-associated pneumoniaâ€™. Expert Review of Anti-Infective Therapy, 2017, 15, 191-192.	4.4	0
191	Reply to Hassoun et al. Clinical Infectious Diseases, 2017, 64, 1633-1634.	5.8	0
192	Response to Letter to the Editor regarding â€œIncidence of ventilator associated pneumonia in burn patients with inhalation injury treated with high frequency percussive ventilation versus volume control ventilation: A systematic reviewâ€. Burns, 2017, 43, 689-690.	1.9	0
193	Reply to Daniels et al.. Clinical Infectious Diseases, 2017, 64, 387-388.	5.8	0
194	Risk Factors for Development of Cytomegalovirus Resistance in Solid Organ Transplantation: AÂRetrospective Nested Caseâ€“Control Study. Open Forum Infectious Diseases, 2017, 4, S732-S732.	0.9	0
195	Hospital Course after TAH Implantation, Nebraska Experience. Transplantation, 2018, 102, S676.	1.0	0
196	Controversies in Nosocomial pneumonias in 2019. Clinical Microbiology and Infection, 2019, 25, 1171-1172.	6.0	0
197	2128. Murine Typhus and Pregnancy: Case Series and Literature Review. Open Forum Infectious Diseases, 2019, 6, S720-S721.	0.9	0
198	2204. Microbiology of Pneumonia Due to Co-Infection in the ICU: Impact of Host Immune Status. Open Forum Infectious Diseases, 2019, 6, S751-S752.	0.9	0

#	Article	IF	Citations
199	2216. Pneumonia in the ICU: Epidemiology and Outcomes. Open Forum Infectious Diseases, 2019, 6, S756-S756.	0.9	0
200	Response. Chest, 2020, 158, 2232.	0.8	0
201	Need for Additional Trials of Vitamin C for Sepsisâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 324, 608.	7.4	0
202	Editorial: COVID-19: A New Severe Infection. Current Opinion in Critical Care, 2021, 27, 461.	3.2	0
203	Controlling the Troll. Annals of Internal Medicine, 2006, 144, 457.	3.9	0
204	Molecular Targets for Therapy. Respiratory Medicine, 2017, , 89-104.	0.1	0
205	1487. Pneumonia due to Co-Infection in the ICU: Detection and Clinical Significance. Open Forum Infectious Diseases, 2020, 7, S745-S746.	0.9	0
206	From Syphilis to Sepsis: Pilot Studies and the Importance of Staying Grounded*. Critical Care Medicine, 2022, 50, 1015-1018.	0.9	0
207	Lower Respiratory Tract Coinfection in the ICU: Prevalence and Clinical Significance of Coinfection Detected via Microbiological Analysis of Bronchoalveolar Lavage Fluid With a Comparison of Invasive Methodologies. , 2022, 4, e0708.		0